{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:31:45Z","timestamp":1793381505637,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.remnie.2026.500322","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:57:18Z","timestamp":1778763438000},"page":"500322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiac amyloidosis: An update on nuclear cardiology in diagnosis and follow-up"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0508-1976","authenticated-orcid":false,"given":"A.","family":"Jim\u00e9nez Heffernan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Orta Tom\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Pubul Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ruano P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.remnie.2026.500322_bib0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","article-title":"Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis","volume":"29","author":"Ando","year":"2022","journal-title":"Amyloid."},{"issue":"5","key":"10.1016\/j.remnie.2026.500322_bib0010","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1053\/j.semnuclmed.2024.05.012","article-title":"Radionuclide imaging of cardiac amyloidosis: an update and future aspects","volume":"54","author":"Clerc","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"2","key":"10.1016\/j.remnie.2026.500322_bib0015","doi-asserted-by":"crossref","DOI":"10.2174\/011573403X240302230925043500","article-title":"Cardiac amyloidosis: a contemporary review of medical and surgical therapy","volume":"20","author":"Brownell","year":"2023","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.remnie.2026.500322_bib0020","first-page":"11","article-title":"A review of recent clinical trials to evaluate disease-modifying therapies in the treatment of cardiac amyloidosis","author":"Senigarapu","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"10.1016\/j.remnie.2026.500322_bib0025","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/CIRCIMAGING.123.015259","article-title":"Rare forms of cardiac amyloidosis: diagnostic clues and phenotype in Apo AI and AIV amyloidosis","volume":"16","author":"Ioannou","year":"2023","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.remnie.2026.500322_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2025.102164","article-title":"March: time to spotlight amyloidosis","author":"Chareonthaitawee","year":"2025","journal-title":"J Nucl Cardiol"},{"issue":"6","key":"10.1016\/j.remnie.2026.500322_bib0035","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2\u2014evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"10.1016\/j.remnie.2026.500322_bib0040","first-page":"254","article-title":"Cardiac scintigraphy with 99mTc-diphosphonates in cardiac amyloidosis","volume":"39","author":"de Haro-del Moral","year":"2020","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"24","key":"10.1016\/j.remnie.2026.500322_bib0045","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.remnie.2026.500322_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.102041","article-title":"American Society of Nuclear Cardiology quality metrics for cardiac amyloid radionuclide imaging","volume":"40","author":"Hage","year":"2024","journal-title":"J Nucl Cardiol"},{"issue":"6","key":"10.1016\/j.remnie.2026.500322_bib0055","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1007\/s12350-023-03256-w","article-title":"Comparison of cardio-focal and chest reconstruction of technetium-99m pyrophosphate scintigraphy for diagnosis of transthyretin cardiac amyloidosis: a quality assurance study","volume":"30","author":"Akincioglu","year":"2023","journal-title":"J Nucl Cardiol."},{"issue":"3","key":"10.1016\/j.remnie.2026.500322_bib0060","article-title":"Role of [99mTc]Tc-DPD gated-SPECT-CT in the assessment of myocardial uptake patterns in transthyretin amyloidosis (TTR-CA)","volume":"44","author":"Sebasti\u00e1n Palacid","year":"2025","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"10.1016\/j.remnie.2026.500322_bib0065","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.2967\/jnumed.122.264866","article-title":"Molecular imaging of systemic and cardiac amyloidosis: recent advances and focus on the future","volume":"64","author":"Dorbala","year":"2023","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.remnie.2026.500322_bib0070","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","article-title":"Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir: A Pilot PET\/CT Study","volume":"16","author":"Clerc","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.remnie.2026.500322_bib0075","article-title":"A tale of two tracers - Amyloid imaging with investigational radiotracers iodine (124I) evuzamitide and 99mTc-p5+14 (AT-05)","author":"Martin","year":"2025","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.remnie.2026.500322_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2025.102146","article-title":"Feasibility of The absolute quantification and left ventricular segmentation of cardiac sympathetic innervation in wild-type transthyretin amyloidosis cardiomyopathy with [123I]-MIBG SPECT\/CT: The I-NERVE study","author":"Tubben","year":"2025","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"10.1016\/j.remnie.2026.500322_bib0085","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s12350-020-02340-9","article-title":"Quantification of amyloid deposition using bone scan agents","volume":"29","author":"Kudo","year":"2022","journal-title":"J Nucl Cardiol."},{"issue":"3","key":"10.1016\/j.remnie.2026.500322_bib0090","first-page":"171","article-title":"Description of a different quantification method for amyloid burden (burdenDPD) and validation of SPECT\/CT in cardiac amyloidosis","volume":"42","author":"Mall\u00f3n Araujo","year":"2023","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"1","key":"10.1016\/j.remnie.2026.500322_bib0095","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12350-022-02960-3","article-title":"Quantitative 99mTc-DPD-SPECT\/CT assessment of cardiac amyloidosis","volume":"30","author":"Kessler","year":"2023","journal-title":"J Nucl Cardiol."},{"issue":"3","key":"10.1016\/j.remnie.2026.500322_bib0100","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00259-023-06459-y","article-title":"Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?","volume":"51","author":"Tingen","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.remnie.2026.500322_bib0105","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcmg.2024.10.011","article-title":"The last decade in cardiac amyloidosis: advances in understanding pathophysiology, diagnosis and quantification, prognosis, treatment strategies, and monitoring response","volume":"18","author":"Fontana","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.remnie.2026.500322_bib0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/ehjci\/jeae295","article-title":"Prognostic implication of DPD quantification in transthyretin cardiac amyloidosis","volume":"26","author":"Rettl","year":"2025","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.remnie.2026.500322_bib0115","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00259-024-06981-7","article-title":"Clinical significance of quantitative assessment of right ventricular amyloid burden with [99mTc]Tc-DPD SPECT\/CT in transthyretin cardiac amyloidosis","volume":"52","author":"Zhao","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"15","key":"10.1016\/j.remnie.2026.500322_bib0120","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.123.066524","article-title":"Clinical and prognostic implications of right ventricular uptake on bone scintigraphy in transthyretin amyloid cardiomyopathy","volume":"149","author":"Porcari","year":"2024","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.remnie.2026.500322_bib0125","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1007\/s10554-024-03231-7","article-title":"The impact of different reconstruction parameters on quantitative 99mTc-DPD SPECT\/CT values in the assessment of cardiac transthyretin amyloidosis","volume":"40","author":"Schepers","year":"2024","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.remnie.2026.500322_bib0130","first-page":"51","article-title":"Test\u2013retest reproducibility of myocardial 99mTc-HMDP uptake quantification by SPECT-CT in suspected transthyretin cardiac amyloidosis","author":"Legallois","year":"2025","journal-title":"J Nucl Cardiol."},{"issue":"5","key":"10.1016\/j.remnie.2026.500322_bib0135","first-page":"302","article-title":"Absolute quantification of myocardial uptake of 99mTc-DPD in patients with cardiac amyloidosis due to transthyretin deposits (ATTR)","volume":"42","author":"Sebasti\u00e1n Palacid","year":"2023","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"6","key":"10.1016\/j.remnie.2026.500322_bib0140","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2967\/jnumed.123.266926","article-title":"Prognostic value of [99mTc]Tc-DPD quantitative SPECT\/CT in patients with suspected and confirmed amyloid transthyretin\u2013related cardiomyopathy and preserved left ventricular function","volume":"65","author":"Caobelli","year":"2024","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.remnie.2026.500322_bib0145","article-title":"DPD Quantification correlates with extracellular volume and disease severity in wild-type transthyretin cardiac amyloidosis","volume":"3","author":"Rettl","year":"2024","journal-title":"JACC: Advances"},{"issue":"5","key":"10.1016\/j.remnie.2026.500322_bib0150","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jcmg.2024.11.003","article-title":"Development of imaging endpoints for clinical trials in AL and ATTR amyloidosis: proceedings of the amyloidosis forum","volume":"18","author":"Dorbala","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.remnie.2026.500322_bib0155","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12350-016-0638-5","article-title":"Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR)","volume":"25","author":"Pilebro","year":"2018","journal-title":"J Nucl Cardiol"},{"issue":"4","key":"10.1016\/j.remnie.2026.500322_bib0160","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/j.semnuclmed.2020.03.001","article-title":"Cardiac imaging with 123I-meta-iodobenzylguanidine and Analogous PET Tracers: current status and future perspectives","volume":"50","author":"Wan","year":"2020","journal-title":"Semin Nucl Med. W.B. Saunders"},{"issue":"4","key":"10.1016\/j.remnie.2026.500322_bib0165","first-page":"262","article-title":"Cardiac sympathetic innervation scintigraphy with 123I-meta-iodobenzylguanidine. Basis, protocols and clinical applications in Cardiology","volume":"38","author":"Cas\u00e1ns-Tormo","year":"2019","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"6","key":"10.1016\/j.remnie.2026.500322_bib0170","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.remnie.2026.500322_bib0175","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0735-1097(96)00438-X","article-title":"Iodine-123 metaiodobenzylguanidinescintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy","volume":"29","author":"Tanaka","year":"1997","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.remnie.2026.500322_bib0180","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1007\/s00259-018-3963-x","article-title":"Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers","volume":"45","author":"Piekarski","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1016\/j.remnie.2026.500322_bib0185","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2967\/jnumed.120.245381","article-title":"Molecular imaging of cardiac amyloidosis","volume":"61","author":"Masri","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remnie.2026.500322_bib0190","doi-asserted-by":"crossref","DOI":"10.1007\/s10741-025-10493-3","article-title":"Positron emission tomography in cardiac amyloidosis: current evidence and future directions","author":"Aimo","year":"2025","journal-title":"Heart Fail Rev"},{"issue":"11","key":"10.1016\/j.remnie.2026.500322_bib0195","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jcmg.2023.08.009","article-title":"Cardiac amyloid detection by PET\/CT Imaging of Iodine (124I) Evuzamitide (124I-p5+14): a phase 1\/2 study","volume":"16","author":"Wall","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.remnie.2026.500322_bib0200","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2967\/jnumed.111.102053","article-title":"In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET","volume":"54","author":"Antoni","year":"2013","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.remnie.2026.500322_bib0205","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","article-title":"Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography","volume":"41","author":"Dorbala","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.remnie.2026.500322_bib0210","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcmg.2020.05.031","article-title":"[18F]-Florbetaben PET\/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions","volume":"14","author":"Genovesi","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11","key":"10.1016\/j.remnie.2026.500322_bib0215","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.remnie.2026.500322_bib0220","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.remnie.2026.500322_bib0225","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/acn3.52158","article-title":"Diflunisal versus tafamidis on neuropathy and cardiomyopathy in hereditary transthyretin amyloidosis","volume":"11","author":"Chao","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"10.1016\/j.remnie.2026.500322_bib0230","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2967\/jnumed.124.268035","article-title":"From stabilization to depletion: molecular imaging to measure therapeutic response in ATTR-CA","volume":"66","author":"Vijayakumar","year":"2025","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.remnie.2026.500322_bib0235","first-page":"98","article-title":"New therapies to treat cardiac amyloidosis","volume":"40","author":"Nguyen","year":"2025","journal-title":"CurrOpinCardiol"},{"issue":"1","key":"10.1016\/j.remnie.2026.500322_bib0240","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.remnie.2026.500322_bib0245","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.remnie.2026.500322_bib0250","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2023.11.016","article-title":"Effect of eplontersen on cardiac structure and function in patients with hereditary transthyretin amyloidosis","volume":"30","author":"Masri","year":"2024","journal-title":"J Card Fail"},{"issue":"1","key":"10.1016\/j.remnie.2026.500322_bib0255","doi-asserted-by":"crossref","DOI":"10.1007\/s11897-025-00701-4","article-title":"Etiological treatment of cardiac amyloidosis: standard of care and future directions","volume":"22","author":"Ferrari Chen","year":"2025","journal-title":"Curr Heart Fail Rep"},{"issue":"2","key":"10.1016\/j.remnie.2026.500322_bib0260","doi-asserted-by":"crossref","first-page":"59","DOI":"10.14797\/mdcvj.1050","article-title":"Cardiac amyloidosis treatment","volume":"18","author":"Stern","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"10.1016\/j.remnie.2026.500322_bib0265","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/0002-8703(92)90986-6","article-title":"Assessment of patient outcome with the Minnesota living with heart failure questionnaire: reliability and validity during a randomized, couble-blind, placebo-controlled trial of pimobendan","volume":"124","author":"Rector","year":"1992","journal-title":"Am Heart J"},{"issue":"7","key":"10.1016\/j.remnie.2026.500322_bib0270","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2967\/jnumed.122.265352","article-title":"Regression of myocardial 99mTc-DPD uptake after tafamidis treatment of cardiac transthyretin amyloidosis","volume":"64","author":"Papathanasiou","year":"2023","journal-title":"J Nucl Med"}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808926000509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808926000509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:54:14Z","timestamp":1793379254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808926000509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2253808926000509"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2026.500322","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac amyloidosis: An update on nuclear cardiology in diagnosis and follow-up","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2026.500322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2026.500322","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500322"}}